#Singapore #Berlin #SCG Cell Therapy #HPV cancer #SCG142

SCG Cell Therapy Presents Results of SCG142 at ESMO 2025

SCG Cell Therapy Pte Ltd (SCG), a leading biotechnology firm dedicated to developing advanced immunotherapies for infectious diseases and cancers, has announced the presentation of its groundbreaking clinical trial results for SCG142. This innovative therapy is specifically designed for patients suffering from recurrent or metastatic carcinomas related to the Human Papillomavirus (HPV). The findings will be shared during the prestigious European Society for Medical Oncology (ESMO) Congress on October 18, 2025, in Berlin, Germany.

Overview of SCG142

SCG142 is an exciting new treatment approach that utilizes a specialized type of T-cell therapy known as T-cell receptor (TCR) T-cell therapy, which has been engineered to specifically target HPV-related cancers. The Phase I trial, identified as NCT06544720, is focused on analyzing the safety, tolerability, and preliminary efficacy of SCG142 in patients with advanced HPV-16 or HPV-52 carcinomas who have either failed previous therapies or were intolerant to them.

The study's early findings have demonstrated promising results. Notably, of the seven patients treated so far, all have shown signs of tumor shrinkage, yielding a remarkable disease control rate (DCR) of 100%. Among these patients, four achieved significant tumor reductions of over 30%, including two confirmed partial responses (PR) and two unconfirmed PRs. Remarkably, there were no reports of serious side effects or dose-limiting toxicities, suggesting that SCG142 is both effective and well-tolerated.

Expert Insights

Prof. Dr. Yang Li, a prominent figure in medical oncology at The First Affiliated Hospital of Guangxi Medical University, shared her enthusiasm about the trial results: "SCG142 is a differentiated therapy specifically targeting HPV, and its potential for clinical activity is encouraging. The fact that tumor shrinkage was observed in all cases strengthens our belief in SCG142 as a viable treatment option for cancers associated with HPV16 and HPV52. This underlines the necessity for further investigation within larger patient groups."

Technology Behind SCG142

The success of SCG142 can be attributed to SCG's proprietary GianTCRTM platform, which enables the identification of high-affinity natural TCRs that can effectively combat infection-related tumors while minimizing the risk of off-target effects. Dr. Susanne Wilde, VP and Head of Preclinical Research at SCG, praised the technology, stating, "We are thrilled that the excellent preclinical performance of our HPV-E7-specific TCR has translated into measurable clinical benefits with SCG142."

Apart from SCG142, SCG is also advancing SCG101, a targeted therapy for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), underscoring their commitment in the field of immunotherapy against infection-related cancers.

The Significance of HPV in Cancer

HPV infection is recognized as the most prevalent sexually transmitted infection globally, affecting nearly all sexually active individuals at some point in their lives. High-risk types of HPV are notorious for their association with various cancers. Current statistics indicate that HPV is responsible for over 90% of anal and cervical cancer cases and significantly contributes to cancers of the vagina, vulva, and oropharynx, leading to approximately 690,000 cancer cases yearly around the world.

Conclusion

The presentation of SCG142's clinical trial results at the ESMO Congress is an exciting development in the ongoing battle against HPV-related cancers. SCG Cell Therapy's promising results not only bring hope to patients but also exemplify the potential advancements in biotechnology aimed at tackling infectious diseases and their associated cancers. For more information about SCG Cell Therapy and its innovative therapies, please visit SCG's website.